Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases.

Wendling D, Paccou J, Berthelot JM, Flipo RM, Guillaume-Czitrom S, Prati C, Dernis E, Direz G, Ferrazzi V, Ristori JM; CRI.

Semin Arthritis Rheum. 2011 Dec;41(3):503-10. doi: 10.1016/j.semarthrit.2011.05.005. Epub 2011 Aug 20.

PMID:
21862108
2.

Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.

Toussirot É, Houvenagel É, Goëb V, Fouache D, Martin A, Le Dantec P, Dernis E, Wendling D, Ansemant T, Berthelot JM, Bader-Meunier B, Kantelip B; Le CRI.

Joint Bone Spine. 2012 Oct;79(5):457-63. doi: 10.1016/j.jbspin.2011.10.001. Epub 2011 Nov 15.

PMID:
22088934
3.

Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.

Kakkassery V, Mergler S, Pleyer U.

Curr Eye Res. 2010 Aug;35(8):751-6. doi: 10.3109/02713683.2010.486520.

PMID:
20673052
4.

Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.

Foeldvari I, Nielsen S, Kümmerle-Deschner J, Espada G, Horneff G, Bica B, Olivieri AN, Wierk A, Saurenmann RK.

J Rheumatol. 2007 May;34(5):1146-50. Epub 2007 Mar 1.

PMID:
17343318
5.

The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.

Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S.

Int J Rheum Dis. 2009 Jul;12(2):118-24. doi: 10.1111/j.1756-185X.2009.01393.x.

PMID:
20374328
6.

Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?

Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N.

Rheumatol Int. 2012 Sep;32(9):2675-9. doi: 10.1007/s00296-011-2030-8. Epub 2011 Jul 26.

PMID:
21789614
7.

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.

De Bandt M, Sibilia J, Le Loët X, Prouzeau S, Fautrel B, Marcelli C, Boucquillard E, Siame JL, Mariette X; Club Rhumatismes et Inflammation.

Arthritis Res Ther. 2005;7(3):R545-51. Epub 2005 Mar 1.

8.

Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.

Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, Feldman BM, Laxer RM, Schneider R, Silverman ED.

Rheumatology (Oxford). 2006 Aug;45(8):982-9. Epub 2006 Feb 3.

PMID:
16461435
9.

Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.

Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, Rosenbaum JT.

Arthritis Rheum. 2001 Jun;45(3):252-7.

10.
11.

Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.

Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K.

Ann Rheum Dis. 2007 Apr;66(4):548-50. Epub 2006 Oct 26.

12.

[Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].

de Oliveira SK, de Almeida RG, Fonseca AR, Rodrigues MC, Sztajnbok F, Diniz C.

Acta Reumatol Port. 2007 Apr-Jun;32(2):139-50. Portuguese.

13.

Adalimumab in the therapy of uveitis in childhood.

Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M.

Br J Ophthalmol. 2007 Mar;91(3):319-24. Epub 2006 Oct 11.

14.

Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents.

Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED.

J Pediatr. 2006 Dec;149(6):833-6.

PMID:
17137902
15.

[Recurrent new-onset uveitis in a patient with rheumatoid arthritis during anti-TNFalpha treatment].

Di Gangi M, Foti R, Leonardi R, Leonetti C, Castellino P.

Reumatismo. 2007 Apr-Jun;59(2):169-72. Italian.

16.

Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.

Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ.

J Med Econ. 2012;15(2):264-75. doi: 10.3111/13696998.2011.644645. Epub 2011 Dec 8.

PMID:
22115327
17.

Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.

Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.

Isr Med Assoc J. 2008 Apr;10(4):277-81.

18.

Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.

Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M.

Br J Dermatol. 2007 Mar;156(3):486-91.

PMID:
17300238
19.

Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study.

Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, Dougados M.

Ann Rheum Dis. 2006 Dec;65(12):1631-4. Epub 2006 Aug 10.

20.

Do tumor necrosis factor inhibitors cause uveitis? A registry-based study.

Lim LL, Fraunfelder FW, Rosenbaum JT.

Arthritis Rheum. 2007 Oct;56(10):3248-52.

Supplemental Content

Support Center